WIMM PI
Curriculum Vitae
Personal Details
Name
Date of Birth
Email
Professor Graham Ogg FRCP DPhil
27.01.67
graham.ogg@ndm.ox.ac.uk
Present Positions
1st October 20101st October 20081st April 20081st April 2007-
Professor of Dermatology, University of Oxford
MRC Programme Leader, Human Immunology Unit
Chairman Thames Valley CLRN Dermatology committee
Sub-theme leader Biomedical Research centre and NIHR
Investigator
1st October 2003Associate Senior Research Fellow, Christ Church, Oxford
31st December 2001- Consultant Dermatologist, Oxford
Previous Positions
31st March 2003-8
MRC Senior Clinical Fellow, University of Oxford
9th April 2006-9
Chairman British Society for Investigative Dermatology
1st September 2006-9 Co-Editor of Clinical and Experimental Dermatology journal
MRC Clinician Scientist Fellow (1.10.98-31.3.03) and Specialist Registrar in Dermatology,
Oxford Region (NTN OXF/005/008 1.1.98-31.12.01) and Junior Research Fellow, Christ
Church (1.10.99-30.9.03)
MRC Clinical Training Fellow (1.1.96-30.9.98), Honorary Registrar in Dermatology, Churchill
Hospital, Oxford (1.1.96-31.12.97), Clinical Lecturer, Magdalen College (1.10.98-30.9.99),
and Senior Scholar Keble College (1.9.96-1.9.98).
SHO St John's Institute of Dermatology, Guy's Hospital, London (1.4.95-30.9.95) - SHO
experience in dermatology (Prof R Hay, Dr JNWN Barker, Dr MacDonald), general
medicine, GU and HIV.
SHO Royal Brompton Hospital, London (1.8.94-31.1.95) - SHO experience in cardiology (Dr
Oldershaw and Prof Poole-Wilson) and ITU (Dr Evans).
SHO Hammersmith Hospital, London (1.2.94-31.7.94) - SHO experience in general
medicine, respiratory medicine (Prof Pride), infectious disease (Prof Cohen), and renal
medicine (Prof Rees).
SHO National Hospital for Neurology, Queen Square, London (1.8.93-31.1.94) - SHO
experience under Profs Marsden, Harding, Frackowiak, Thomas.
Research Achievements
I have been fascinated by the cellular immune system since my FHS project in 1989 under
the supervision of Professor Andrew McMichael. I was part of an exciting group and shared
in the achievements of the team. This included the first application of the use of HLA
tetrameric complexes to questions relevant to disease pathogenesis (HIV) and the
identification of CD94 as being a ligand for HLA-E. I wanted to apply my T cell knowledge
to the understanding of human skin disease, as dermatology is my clinical specialty. One of
the earliest achievements was working with Professor Vincenzo Cerundolo in which we
showed that individuals with vitiligo have high frequencies of circulating melanocyte-specific
T cells – this has been confirmed in many subsequent studies by others, and a potential role
of such T cells in disease has been suggested by the acquisition of pigment loss in patients
with melanoma treated with melanocyte-specific T cell infusions. Since having my own
group under the support of an MRC Senior Clinical Fellowship, I have focused on atopic skin
disease. We have made several contributions, but the most significant has been the finding
that staphylococcal superantigen can enhance keratinocyte presentation of allergen to T
cells – this fits with clinical observations and has therapeutic implications which we are
investigating in an MRC Experimental Medicine clinical trial. More recently, in collaboration
with Professor Cerundolo, we have found that allergen-derived phospholipase can generate
fatty acids which are novel ligands for CD1a, and can be presented to CD1a-restricted T
cells from human skin. We believe that this is an important finding, not only for CD1a and
Langerhans cell biology, but for many forms of cutaneous inflammation and is a key focus of
our ongoing work. I continue to do two clinics per week in dermatology at the Churchill
hospital. This has been invaluable as a resource for understanding disease and for access
to clinical samples from well-defined cohorts and the translation of our findings to clinical
trials.
What are the Future Aims of Your Current Group
The overall aim of the group is to understand the pathogenesis of cutaneous inflammatory
disease in order to inform new approaches to disease prevention and treatment. The
studies will contribute to our understanding of the interaction between the epithelium and the
innate and adaptive immune response. Emphasis will be focused on: 1) understanding
mechanisms underlying CD1a presentation of lipid antigens to T cells in the skin; 2)
characterising innate IL-13 producing cells in human lesional atopic skin and after antigen
challenge; 3) how filaggrin insufficiency promotes atopic inflammation and whether this can
be therapeutically modified; 4) investigating mechanisms underlying the cellular immune
response to viral antigens in human skin. As well as contributing to disease and tissue
specific questions, these studies will advance the broader Unit aims of defining the
interactions between the innate and adaptive immune responses and the local microenvironment, which in turn will support the development of new approaches to vaccination
and treatment.
How do the aims of your research fit with the aims of the WIMM and Division of
Medicine?
The work of the group is directly informed by clinical observation from patients we see in
clinic, and is then translated back to the patients. This is illustrated, for example, by the
staphylococcal superantigen work described above which is now been tested in an MRC
Experimental Medicine clinical trial. We aim to understand disease by studying samples
from humans, but also using models, as required, to investigate underlying mechanisms that
may lead to opportunities for therapeutic intervention. In particular, I believe that the CD1a
work is likely to be significance in many human skin diseases, although our initial focus will
be on atopic eczema and psoriasis. As well as scientific research to contribute to the
understanding and management of human disease, we are also contributing to the training
of scientists and academic clinicians. Over the last 10 years, there have been 9 DPhils
completed, of which 6 were by clinicians – there are four current DPhil students in the
laboratory. There have been many others in training who have had periods in the laboratory
including MSc students, medical students, academic F1/F2, clinical lecturers, academic
clinical fellows and overseas visitors. We aim to function within networks to enhance
opportunities for success, including integral links with the BRC, NHS, Comprehensive Local
Research Network and we participate in local and multicenter clinical trials. The work
involves local, national and international collaborations - key collaborators are Vincenzo
Cerundolo, Paul Klenerman, Andrew McKenzie (LMB), Branch Moody (Harvard). We also
contribute to the work of the institute towards the public understanding of science, including
participation in National Science and Engineering Week (several talks) and the Royal
Society Summer Exhibition (2002).
Lay Summary of Research
We are working towards treatment and prevention of skin disease. The skin is often the first
point of contact with pathogens and allergens, but relatively little is understood about how
the cutaneous immune system clears these challenges. Such knowledge is vitally important
to understanding the mechanisms of skin disease and related diseases, and for developing
more effective ways of cutaneous drug and vaccine delivery.
It is increasingly clear that skin barrier dysfunction is an important first step in the
development of atopic eczema, one of the commonest skin diseases in the UK, and often
associated with asthma and rhinitis. The barrier dysfunction promotes entry of allergens
and microbes which eventually lead to skin inflammation. The latter is treated with topical
immune suppressants, but these are not curative and also carry risks of side effects.
We wish to understand the steps linking barrier dysfunction and skin inflammation, as these
will provide opportunities for new treatments. In particular, we will explore ways to repair
barrier function and to understand the roles of novel immune cells in contributing to the
inflammation.
These findings will have implications for atopic eczema, but also for other forms of
inflammatory skin disease and indeed for the improvement of vaccine delivery in to the skin.
All Publications Over the Past 5 Years
1.
Xue L, Salimi M, Panse I, Mjosberg JM, McKenzie AN, Spits H, Klenerman P, Ogg
G. Prostaglandin D2 activates group 2 innate lymphoid cells via CRTH2. Journal Allergy
Clinical Immunology. 2013;In press.
2.
Wang X, Salimi M, Gutowska-Owsiak D, Ogg G. Filaggrin modulates the
proliferation, differentiation and apoptosis of keratinocytes. Submitted. 2013.
3.
Vukmanovic-Stejic M, Sandhu D, Sobande TO, Agius E, Lacy KE, Riddell N, Montez
S, Dintwe OB, Scriba TJ, Breuer J, Nikolich-Zugich J, Ogg G, Rustin MH, Akbar AN.
Varicella zoster-specific CD4+Foxp3+ T cells accumulate after cutaneous antigen challenge
in humans. J Immunol. 2013 Feb 1;190(3):977-86.
4.
Salimi M, Barlow JL, Saunders SP, Xue L, Gutowska-Owsiak D, Wang X, Huang L,
Johnson D, Scanlon ST, McKenzie AN, Fallon GP, Ogg G. A role for IL-25 and IL-33-driven
type-2 innate lymphoid cells in atopic dermatitis. Journal of Experimental Medicine. 2013;In
press.
5.
Pan X, Huang L, Dong T, Peng Y, Cerundolo V, McGowan S, Ogg G. Combinatorial
HLA-peptide bead libraries for high throughput identification of CD8+ T cell specificity
Submitted. 2013.
6.
Malavige GN, Jeewandara C, Alles KM, Salimi M, Gomes L, Kamaladasa A,
Jayaratne SD, Ogg GS. Suppression of virus specific immune responses by IL-10 in acute
dengue infection. PLoS Negl Trop Dis. 2013;7(9):e2409.
7.
Malavige GN, Gomes L, Alles L, Chang T, Salimi M, Fernando S, Nanayakkara KD,
Jayaratne S, Ogg GS. Serum IL-10 as a marker of severe dengue infection. BMC Infect Dis.
2013;13(1):341.
8.
Malavige G, Ogg G. T cell responses in dengue viral infections. Journal Clinical
Virology. 2013;in press.
9.
Huang L, Pan X, Yang H, Wan LKD, Stewart-Jones G, Dorrell L, Ogg G. Linking
genotype to phenotype on beads: high throughput selection of peptides with biological
function. Scientific Reports. 2013;3:3030.
10.
Gutowska-Owsiak D, Selvakumar TA, Salimi M, Taylor S, Ogg G. Histamine
enhances keratinocyte-mediated resolution of inflammation by promoting wound healing and
response to infection. submitted. 2013.
11.
Gutowska-Owsiak D, Salimi M, Selvakumar TA, Wang X, Taylor S, Ogg G.
Histamine exerts multiple effects on expression of genes associated with epidermal barrier
function. J Investig Allergol Clin Immunol. 2013;In press.
12.
Gutowska-Owsiak D, Ogg GS. Cytokine regulation of the epidermal barrier. Clin Exp
Allergy. 2013 Jun;43(6):586-98.
13.
Xue L, Barrow A, Fleming VM, Hunter MG, Ogg G, Klenerman P, Pettipher R.
Leukotriene E4 activates human Th2 cells for exaggerated proinflammatory cytokine
production in response to prostaglandin D2. J Immunol. 2012 Jan 15;188(2):694-702.
14.
Malavige GN, McGowan S, Atukorale V, Salimi M, Peelawatta M, Fernando N,
Jayaratne SD, Ogg G. Identification of serotype-specific T cell responses to highly
conserved regions of the dengue viruses. Clin Exp Immunol. 2012 May;168(2):215-23.
15.
Malavige G, Ogg G. Pathogenesis of severe dengue infection. Ceylon Medical
Journal. 2012;57:97-100.
16.
Malavige G, Huang L, Salimi M, Gomes L, Jayaratne SD, Ogg G. Cellular and
cytokine correlates of severe dengue infection. PLoS ONE. 2012;7(11):e50387.
17.
Jayaratne SD, Gomes L, Ogg G, Malavige G. Evaluation of the WHO revised criteria
for classification of clinical disease severity in acute adult dengue infection. BMC Research.
2012;In press.
18.
Gutowska-Owsiak D, Schaupp AL, Salimi M, Selvakumar TA, McPherson T, Taylor
S, Ogg GS. IL-17 downregulates filaggrin and affects keratinocyte expression of genes
associated with cellular adhesion. Exp Dermatol. 2012 Feb;21(2):104-10.
19.
Gutowska-Owsiak D, salimi M, Taylor S, Wang X, Ogg G. Histamine modulates
keratinocyte differentiation and expression of genes associated with epidermal barrier
function. Submitted. 2012.
20.
Gutowska-Owsiak D, Ogg GS. The epidermis as an adjuvant. J Invest Dermatol.
2012 Mar;132(3 Pt 2):940-8.
21.
Gutowska-Owsiak D, Ogg G. Cytokine regulation of the epidermal barrier. Clinical &
Experimental Allergy. 2012;21(2):104-10.
22.
Crack LR, Chan HW, McPherson T, Ogg GS. Identification of an immunodominant
region of the major house dust mite allergen Der p 2 presented by common human
leucocyte antigen alleles. Clin Exp Dermatol. 2012 Apr;37(3):266-76.
23.
Crack L, Jones L, Chan H, McPherson T, Ogg G. Human Anti-microbial Peptides LL37 and Human β-defensin-2 reduce viral load replication in varicella zoster virus-vaccine
infected keratinocytes. Clin Exp Dermatol. 2012;37:534-43.
24.
Malavige GN, Rostron T, Rohanachandra LT, Jayaratne SD, Fernando N, De Silva
AD, Liyanage M, Ogg G. HLA class I and class II associations in dengue viral infections in a
Sri Lankan population. PLoS ONE. 2011;6(6):e20581.
25.
Gutowska-Owsiak D, Schaupp AL, Salimi M, Taylor S, Ogg GS. Interleukin-22
downregulates filaggrin expression and affects expression of profilaggrin processing
enzymes. Br J Dermatol. 2011 Sep;165(3):492-8.
26.
Gomes PL, Malavige GN, Fernando N, Mahendra MH, Kamaladasa SD, Seneviratne
JK, Karunatilaka DH, Ogg GS. Characteristics of Staphylococcus aureus colonization in
patients with atopic dermatitis in Sri Lanka. Clin Exp Dermatol. 2011 Mar;36(2):195-200.
27.
Crack LR, Chan HW, McPherson T, Ogg GS. Phenotypic analysis of perennial
airborne allergen-specific CD4+ T cells in atopic and non-atopic individuals. Clin Exp
Allergy. 2011 Nov;41(11):1555-67.
28.
Aslam A, Lloyd-Lavery A, Warrell DA, Misbah S, Ogg GS. Common filaggrin null
alleles are not associated with hymenoptera venom allergy in Europeans. Int Arch Allergy
Immunol. 2011;154(4):353-5.
29.
Aslam A, Chapel H, Ogg G. Direct ex-vivo evaluation of pneumococcal specific Tcells in healthy adults. PLoS ONE. 2011;6(10):e25367.
30.
Aly L, Yousef S, Schippling S, Jelcic I, Breiden P, Matschke J, Schulz R, Bofill-Mas
S, Jones L, Demina V, Linnebank M, Ogg G, Girones R, Weber T, Sospedra M, Martin R.
Central role of JC virus-specific CD4+ lymphocytes in progressive multi-focal
leucoencephalopathy-immune reconstitution inflammatory syndrome. Brain. 2011
Sep;134(Pt 9):2687-702.
31.
McPherson T, Sherman VJ, Aslam A, Crack L, Chan H, Lloyd-Lavery A, Jones L,
Ardern-Jones M, Ogg G. Filaggrin null mutations associate with increased frequencies of
allergen-specific CD4+ Th2 cells in patients with atopic eczema. Br J Dermatol. 2010 May
25;163:544-9.
32.
McPherson T, Aslam A, Crack L, Chan H, Jones L, Ogg G. Frequencies of
circulating allergen-specific T cells temporally associate with longitudinal changes in severity
of cutaneous atopic disease. Clin Exp Dermatol. 2010;35:786-8.
33.
Malavige GN, Rohanachandra LT, Jones L, Crack L, Perera M, Fernando N, Guruge
D, Ogg GS. IE63-specific T-cell responses associate with control of subclinical varicella
zoster virus reactivation in individuals with malignancies. Br J Cancer. 2010 Feb
16;102(4):727-30.
34.
Malavige GN, Jones L, Kamaladasa SD, Wijewickrama A, Seneviratne SL, Black AP,
Ogg GS. Natural killer cells during primary varicella zoster virus infection. J Infect. 2010
Jul;61(2):190-2.
35.
Baldo M, Bailey A, Bhogal B, Groves RW, Ogg G, Wojnarowska F. T cells reactive
with the NC16A domain of BP180 are present in vulval lichen sclerosus and lichen planus. J
Eur Acad Dermatol Venereol. 2010 Feb;24(2):186-90.
36.
Aslam A, Mason A, Zemenides S, Chan H, Novakova L, Branny P, Finn A, Chapel H,
Ogg GS. Rapid effector function of circulating CD4+ T cells specific for immunodominant
regions of the conserved serine/threonine kinase found in Streptococcus pneumoniae
(StkP) in healthy adults. FEMS Immunol Med Microbiol. 2010 Nov;60(2):113-22.
37.
Aslam A, Chan H, Warrell DA, Misbah S, Ogg GS. Tracking antigen-specific T-cells
during clinical tolerance induction in humans. PLoS ONE. 2010;5(6):e11028.
38.
Ogg G. Role of T cells in the pathogenesis of atopic dermatitis. Clin Exp Allergy.
2009 Mar;39(3):310-6.
39.
McPherson T, Ogg G. Spontaneous resolution of basal cell carcinoma in naevoid
basal cell carcinoma syndrome/Gorlin's syndrome. Clin Exp Dermatol. 2009
Dec;34(8):e884-5.
40.
Jones L, Malavige G, Jeffery K, Kemp E, Breuer J, Klenerman P, Ogg GS. Tracking
epitope-specific antiviral CD4(+) T cell responses to a live attenuated vaccine reveals
ongoing functional responses. Vaccine. 2009 Sep 8;27:7398-401.
41.
Horlock C, Stott B, Dyson J, Ogg G, McPherson T, Jones L, Sewell AK, Wooldridge
L, Cole DK, Stebbing J, Savage P. ELISPOT and functional T cell analyses using HLA
mono-specific target cells. J Immunol Methods. 2009 Sep 1;350:150-60.
42.
Black A, Jones L, Malavige GN, Ogg G. Immune evasion during varicella zoster virus
infection of keratinocytes. Clin Exp Dermatol. 2009;I34:e941-4.
43.
Baldo M, Bailey A, Bhogal B, Groves RW, Ogg G, Wojnarowska F. T cells reactive
with the NC16A domain of BP180 are present in vulval lichen sclerosus and lichen planus. J
Eur Acad Dermatol Venereol. 2009 Aug 14.
44.
Malavige GN, Seneviratne SL, Black A, Ogg G. Viral load, clinical disease severity
and cellular immune responses in primary varicella zoster virus infection. PLoS ONE.
2008;3:e3789.
45.
Malavige GN, Jones L, Black AP, Ogg GS. Varicella zoster virus glycoprotein Especific CD4(+) T cells show evidence of recent activation and effector differentiation,
consistent with frequent exposure to replicative cycle antigens in healthy immune donors.
Clin Exp Immunol. 2008 Mar 20;152:522-31.
46.
Bateman E, Ardern-Jones M, Ogg G. Identification of an immunodominant region of
Fel d 1 and characterization of constituent epitopes. Clin Exp Allergy. 2008;38:1760-8.
47.
Ardern-Jones M, Black A, Ogg G. Anti-LFA-1 inhibits Th2 function of human
allergen-specific CD4+ T cells. British Journal of Dermatology. 2008;158:456-62.
Ten Key Publications Throughout your Career
Braud VM, Allan DSJ, O'Callaghan CA, Soderstrom K, D'Andrea A, Ogg GS, Lazetic S,
Young NT, Bell JI, Phillips JH, Lanier LL, McMichael AJ. HLA-E binds to natural killer cell
receptors CD94/NKG2A, B and C. Nature. 1998;391:795-9.
Ogg G, Jin X, Bonhoeffer S, Dunbar P, Nowak M, Monard S, Segal J, Cao Y, RowlandJones S, Cerundolo V, Hurley A, Markowitz M, Ho D, Nixon D, McMichael A. Quantitation
of HIV-specific CTL and plasma load of viral RNA. Science. 1998;279:2103-6.
Ogg GS, Dunbar PR, Romero P, Chen JL, Cerundolo V. High frequency of skin-homing
melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med.
1998;188:1203-8.
Champagne P, Ogg G, King AS, Knabenhans C, Ellefsen K, Nobile M, Appay V, Rizzardi
GP, Fleury S, Lipp M, Forster R, Rowland-Jones S, Sekaly RP, McMichael AJ, Panataleo
G. Skewed maturation of memory HIV-specific CD8+ T lymphocytes. Nature.
2001;410:106-11.
Seneviratne SL, Jones L, King AS, Black A, Powell S, McMichael AJ, Ogg GS. Allergenspecific CD8(+) T cells and atopic disease. J Clin Invest. 2002 Nov;110(9):1283-91.
Ardern-Jones M, Black A, Bateman E, Ogg G. Bacterial superantigen facilitates epithelial
presentation of antigen to Th2 cells. Proc Natl Acad Sci U S A. 2007;104:5557-62.
Malavige GN, Seneviratne SL, Black A, Ogg G. Viral load, clinical disease severity and
cellular immune responses in primary varicella zoster virus infection. PLoS ONE.
2008;3:e3789.
Aslam A, Chan H, Warrell DA, Misbah S, Ogg GS. Tracking antigen-specific T-cells during
clinical tolerance induction in humans. PLoS ONE. 2010;5(6):e11028.
Xue L, Salimi M, Panse I, Mjosberg JM, McKenzie AN, Spits H, Klenerman P, Ogg G.
Prostaglandin D2 activates group 2 innate lymphoid cells via CRTH2. Journal Allergy
Clinical Immunology. 2013;In press.
Salimi M, Barlow JL, Saunders SP, Xue L, Gutowska-Owsiak D, Wang X, Huang L, Johnson
D, Scanlon ST, McKenzie AN, Fallon GP, Ogg G. A role for IL-25 and IL-33-driven type-2
innate lymphoid cells in atopic dermatitis. Journal of Experimental Medicine. 2013;In
press.
Markers of Esteem
2007
Pharmacia Allergy Research Foundation Award
(International award for recognition of meritorious research)
2007
Dermatologist International Achievement Award
(awarded by International League of Dermatological Societies for contribution to
international dermatology)
2006
Pharmacia Allergy Research Foundation honour
(honour for international allergy research)
2005
FRCP
2002
Young Investigator of the Year Award
(Medical Research Society/Academy of Medical Sciences)
2001
Young Investigator of the Year Award
(British Society for Investigative Dermatology)
2000
British Assoc Dermatologists AAD Award
2000
American Academy of Dermatology scholarship
2000
Junior Research Fellowship (Christ Church, Oxford)
1999
Unilever Prize, British Society for Investigative Dermatology
1999
Glaxo-Wellcome Prize, British Society for Investigative Dermatology
1996
Senior Scholarship Keble College Oxford
1995
MRCP
1992
Gotch Memorial Prize for meritorious postgraduate research
(University of Oxford)
1992
3M Health Care elective essay prize
(University of Oxford)
1991
President's Award - Society for General Microbiology
1991
Royal College of Pathologists Student Award
1990
Hobson Memorial Scholarship (University of Oxford)
1989
Martin Wronker Prize in Medicine –
for highest First Class degree in University of Oxford
1989
Trinity College Examination Prize – for First Class honours
1989
RA Knox Memorial Prize (Trinity College) –
for highest performance in finals across all subjects
1989
Green College Texas Instruments Computing Scholarship
(re-awarded in 1990)
1988
Douglas Sladen Essay Prize (Trinity College)
1983
Sunday Times 'Young Brain of Britain'
Grant Support
(approximate values)
2013-2015
Janssen Pharmaceuticals
£1,000,000
2003-2012 (ongoing) MRC Human Immunology Unit
£500,000
2011-2013
£35,000
British Medical Association (with Paul Klenerman)
2007-2012 (ongoing) Oxford Biomedical Research Centre
£650,000
2008-2012 (ongoing) Comprehensive Local Research Network
£300,000
2012-2015
MRC Clin Training F’Ship (Rachael Jarrett supervision)
£300,000
2004-2009
Commonwealth PhD Scholarships
(Drs Malavige & Chan supervision)
£200,000
2009-2012
Health Research Council (with Rod Dunbar)
£500,000
2009-2013
MRC Experimental Medicine 2
£360,000
2008-2012
British Skin Foundation
£75,000
2003-2008
MRC Senior Clinical Fellowship
£990,000
2004-2007
Wellcome Trust Clinical Training F’ship
(Dr M Ardern-Jones supervision)
£185,000
2004-2007
MRC Clinical Training F’ship (Dr A Aslam supervision)
£140,000
1997-2008
Barrie Trust
£70,000
2005-2007
Wellbeing (joint with Prof Wojnarowska)
£47,000
1996-1998
MRC Clinical Training Fellowship
£170,000
1999-2003
MRC Clinician Scientist Fellowship
£360,000
1999-2003
National Institutes for Health (joint with Dr Doug Nixon)
£90,000
1999-2002
Commonwealth PhD Scholarship
(Dr S Seneviratne supervision)
£100,000
2000-2002
British Skin Foundation
£94,000
2003-2006
MRC Studentship (Elizabeth Bateman supervision)
£35,000